Geron to Present at the 21st Annual Needham Virtual Healthcare Conference
April 06 2022 - 4:30PM
Business Wire
Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical
company focused on the development and commercialization of
treatments for hematologic malignancies, today announced that John
A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer,
plans to present a company overview at the 21st Annual Needham
Virtual Healthcare Conference on Wednesday, April 13, 2022 at 3:45
p.m. ET.
A live webcast of the presentation will be available through the
Investor Relations section of Geron’s website under Events.
Following the presentation, the webcast will be archived and
available for replay for a period of 30 days.
About Geron
Geron is a late-stage clinical biopharmaceutical company focused
on the development and potential commercialization of a
first-in-class telomerase inhibitor, imetelstat, in hematologic
malignancies. The Company currently is conducting two Phase 3
clinical trials: IMerge in lower risk myelodysplastic syndromes and
IMpactMF in refractory myelofibrosis.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220406005098/en/
Aron Feingold Investor and Media Relations investor@geron.com
media@geron.com
Geron (NASDAQ:GERN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Geron (NASDAQ:GERN)
Historical Stock Chart
From Sep 2023 to Sep 2024